Precision Biosciences INC 8-K filings

Precision BioSciences announced second quarter 2026 financial results, highlighting key clinical advancements in its PBGENE-HBV and PBGENE-DMD programs, and a cash runway extending through 2028.

Precision BioSciences has appointed a new Chief Operating Officer and Chief Financial Officer, effective August 1, 2026, to support program advancement.

Precision BioSciences reports clinical highlights for PBGENE-HBV and initiates the FUNCTION-DMD trial, targeting year-end updates for both programs.

Precision BioSciences has amended its loan and security agreement, extending the maturity date of its term loan to December 31, 2029.

Precision BioSciences presented new clinical data from its PBGENE-HBV trial at EASL 2026, showing direct elimination of cccDNA in chronic hepatitis B patients.

Precision BioSciences held its annual stockholder meeting, approving key plan amendments and director elections.

Precision BioSciences reported Q1 2026 results, highlighting advancements in its gene editing programs for Hepatitis B and Duchenne Muscular Dystrophy, alongside a cash balance projected to fund operations through 2028.

Precision BioSciences announced progress in its PBGENE-DMD program, including site activation for the FUNCTION-DMD Phase 1/2 clinical trial targeting Duchenne muscular dystrophy, with initial patient data expected by late 2026.

Precision BioSciences announced its Q4 and FY 2025 financial results, highlighting significant clinical progress in gene editing programs and an extended cash runway through 2028.

Precision BioSciences announced FDA clearance of its Investigational New Drug application for PBGENE-DMD, enabling the initiation of its Phase 1/2 clinical study for Duchenne muscular dystrophy.

Precision BioSciences reports $137 million cash, extending its runway through 2028, and outlines key clinical milestones for its gene editing programs in 2026.

Precision BioSciences announced an underwritten offering of common stock and warrants, expecting to raise approximately $75 million in gross proceeds to fund research and development.

Precision BioSciences announced positive Phase 1 ELIMINATE-B clinical trial data for PBGENE-HBV, showing dose-dependent antiviral activity and a favorable safety profile for chronic Hepatitis B.

Precision BioSciences reported Q3 2025 financial results and provided updates on its gene editing pipeline, including progress for PBGENE-HBV and PBGENE-DMD.

Precision BioSciences, Inc. has amended employment agreements for its Section 16 officers, including new severance and escrow provisions.

Precision BioSciences reports Q2 2025 financial results, highlights positive clinical data for PBGENE-HBV, accelerates PBGENE-DMD, and extends cash runway to H2 2027.

Precision BioSciences announced positive Phase 1 safety and efficacy data for its PBGENE-HBV gene editing therapy for chronic hepatitis B, extending its cash runway to mid-2027.

Precision BioSciences, Inc. announced the results of its annual stockholder meeting, where directors were re-elected and the auditor ratified, but a proposed amendment to the Certificate of Incorporation regarding officer exculpation failed to pass.

Precision BioSciences reports encouraging clinical data from its ARCUS platform and provides a business update alongside its Q1 2025 financial results, highlighting progress in gene editing therapies.

Precision BioSciences is prioritizing and accelerating the development of PBGENE-DMD, a gene editing approach for Duchenne Muscular Dystrophy, and presented pre-clinical evidence at the ASGCT Annual Meeting.

Precision BioSciences announces positive clinical data from its ARCUS gene editing platform and reports its financial results for the fourth quarter and fiscal year ended December 31, 2024, projecting a cash runway into the second half of 2026.

Precision BioSciences reclassified its Board of Directors' membership following the resignation of Sam Wadsworth, Ph.D., resulting in changes to the classes of Michael Amoroso and Melinda Brown and a reduction in the board size.

Precision BioSciences announces the resignation of director Sam Wadsworth, Ph.D., effective January 23, 2025, due to his retirement from company boards.

Precision BioSciences anticipates a cash balance of $108.5 million at the end of 2024 and expects its cash runway to extend into the second half of 2026.

Precision BioSciences announced its third quarter 2024 financial results and provided a business update, highlighting the advancement of its gene editing programs, including the first clinical trial application approval for PBGENE-HBV.

Precision BioSciences has received its first clinical trial application approval in Moldova for its PBGENE-HBV program, a gene editing therapy for chronic hepatitis B.

Precision BioSciences has announced key leadership changes, including the retirement of its Chief Medical Officer and the appointment of new clinical development leaders, as it prepares to advance its hepatitis B program.

Precision BioSciences received $13 million from the maturity of a convertible note related to the Imugene strategic transaction, strengthening its financial position.

Precision BioSciences announced positive second quarter 2024 financial results, highlighted by a significant increase in revenue and progress in its gene editing programs, including a strengthened cash position.

Precision BioSciences' stockholders approved an amendment to the 2019 Incentive Award Plan, increasing the number of shares available for issuance by 630,000.